Tesamorelin Therapy in San Diego, CA — Peptide for Visceral Fat Loss
Tesamorelin peptide therapy in San Diego — physician-supervised GHRH analog protocol for visceral fat reduction and body composition. By Dr. Joseph Dubroff, N.D.
The Only Peptide with FDA Approval Specifically for Visceral Fat.
Tesamorelin is a stabilized analog of GHRH — similar in family to sermorelin and CJC-1295, but with a different molecular profile and a very different clinical track record. Unlike most peptides in current use, tesamorelin is FDA-approved as a drug (under the brand name Egrifta) for a specific clinical condition: HIV-related lipodystrophy, a syndrome characterized by accumulation of stubborn visceral abdominal fat.
The reason that approval matters for the broader picture is that the clinical trial data behind it — multiple large studies showing measurable, statistically significant reductions in visceral adipose tissue — applies mechanistically to visceral fat in general, not only the HIV-related variety. That makes tesamorelin one of the few interventions with high-quality evidence specifically targeting the metabolically dangerous belly fat that surrounds organs, as opposed to the subcutaneous fat sitting just under the skin.
In Dr. Dubroff's practice, tesamorelin is prescribed off-label for patients with stubborn visceral adiposity — particularly metabolically healthy patients who have done the diet and exercise work but can't shift the abdominal weight, and patients dealing with the body composition shifts of perimenopause, menopause, andropause, or aging in general.
Not All Fat Is the Same Fat.
The "stubborn belly fat" people struggle to lose is not all the same tissue — and tesamorelin specifically targets the most metabolically problematic kind.
Visceral Fat
The deeper abdominal fat that surrounds your organs (liver, pancreas, intestines). This is the metabolically active, inflammatory fat associated with increased cardiovascular risk, insulin resistance, and metabolic syndrome.
Visceral fat tends to be the most resistant to diet and exercise — particularly as hormones decline with age. It's also the fat tesamorelin has been shown to specifically and measurably reduce in clinical trials. This is the target.
Subcutaneous Fat
The fat directly under the skin — the "pinchable" fat. Generally less metabolically active and less dangerous from a cardiovascular standpoint, though it still affects how you look and feel.
Subcutaneous fat responds more reliably to traditional diet and exercise interventions. It's not the primary target of tesamorelin, although some patients do see modest improvements here as part of overall body composition changes.
When Tesamorelin Makes Sense.
Tesamorelin is a specialty peptide with a specific use case. It's not a general weight-loss drug, and Dr. Dubroff doesn't position it that way. Patients who tend to benefit most fit one of these profiles:
- Stubborn visceral fat despite diet and exercisePatients who have done the work — clean eating, consistent training — and still carry significant abdominal weight that won't budge. Often a hormonal or genetic predisposition driving the pattern.
- Perimenopausal and menopausal body composition shiftsThe classic menopause "thickening through the middle" — driven by hormonal shifts that reroute fat storage to the abdomen. Tesamorelin pairs well with bioidentical HRT for this pattern.
- Andropause and post-50 menMen whose testosterone has declined and who are accumulating belly fat despite no major change in diet or training. Often paired with TRT or enclomiphene for a more comprehensive approach.
- Metabolic syndrome and pre-diabetes patientsPatients with elevated visceral fat driving insulin resistance and inflammation. Tesamorelin can be part of a broader metabolic intervention alongside diet, exercise, and other tools.
- Body composition optimization (informed choice)Patients with specific aesthetic or performance goals who want a more targeted intervention than general GH-axis peptides offer — particularly when used alongside structured training and nutrition.
Tesamorelin FAQs
The Stubborn Belly Fat That Won't Listen to Anything Else.
Book a free consultation. Dr. Dubroff will run baseline labs, talk through whether tesamorelin fits your case, and help you decide between peptide therapy, GLP-1, or a combined approach.